Active, not recruitingPhase 2NCT06355531
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
Studying Classic progressive supranuclear palsy syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ferrer Internacional S.A.
- Intervention
- FNP-223(drug)
- Enrollment
- 241 enrolled
- Eligibility
- 50-80 years · All sexes
- Timeline
- 2024 – 2026
Study locations (30)
- The Neurology Center of Southern California - Carlsbad, Carlsbad, California, United States
- UCSF Weill Institute for Neurosciences, San Francisco, California, United States
- Rocky Mountain Movement Disorders Center, Denver, Colorado, United States
- University of Miami Miller School of Medicine, Miami, Florida, United States
- Augusta University, Augusta, Georgia, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Quest Research Institute, Farmington Hills, Michigan, United States
- Robert & John M. Bendheim Parkinson and Movement Disorders Center at Mount Sinai, New York, New York, United States
- Columbia University Irving Medical Center, New York, New York, United States
- Duke Neurology, Durham, North Carolina, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- Central Texas Neurology Consultants, Round Rock, Texas, United States
- Groupe Hospitalier Pellegrin, Bordeaux, France
- Hôpital de la Timone, Marseille, France
- L'Hôpital Universitaire Carémeau, Nîmes, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06355531 on ClinicalTrials.govOther trials for Classic progressive supranuclear palsy syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07509125Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic DisordersUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGEARLY PHASE1NCT07348276First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the BrainInvicro
- RECRUITINGNANCT07291687tDCS as Treatment for Motor FunctionBaycrest
- ACTIVE NOT RECRUITINGNANCT06588673Art Therapy in Progressive Supranuclear PalsyVanderbilt University Medical Center
- ENROLLING BY INVITATIONNANCT06597071Parkinson Atypical Rating of Oculometric Patterns Evaluated RoutinelyNeuraLight
- RECRUITINGNCT06949865AI-Enhanced Optimization of Acute Levodopa Challenge TestBeijing Tiantan Hospital
- RECRUITINGNANCT06174948The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related DisordersQueen Mary University of London
- RECRUITINGNCT06529744Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative ModelingUniversity Health Network, Toronto
See all trials for Classic progressive supranuclear palsy syndrome →